Shares replace cash fees for Geron (GERN) director Robert J. Spiegel, who acquired 6,351 shares.
Geron Corp (GERN) director Robert J. Spiegel acquired 6,351 common shares on September 30, 2026, as compensation for quarterly board retainer and committee fees, rather than receiving cash. The share count was determined by the closing price of $1.23 on that day. Following this transaction, Spiegel directly holds 212,161 shares in the company.
Total common shares outstanding of Geron Corporation – HAN:GON
This article provides financial information for Geron Corporation (HAN:GON) on the Hannover Stock Exchange, specifically focusing on its total common shares outstanding. It appears to be a data point from a financial platform like TradingView, indicating a value for the shares outstanding over a given period.
Geron Corporation Revenue Breakdown – HAN:GON
Geron Corporation reported a revenue of 156.56 million EUR last year, with its Therapeutic Products for Oncology segment being the sole and top-performing contributor. This revenue primarily originated from the United States, marking a significant increase from the 74.37 million EUR reported in the previous year.
Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN
Kahn Swick & Foti, LLC (KSF) has launched an investigation into Geron Corporation (NasdaqGS: GERN) and its officers and directors. This follows a securities class action lawsuit against Geron, alleging that the company failed to disclose material information regarding the growth of its primary product, imetelstat (Rytelo), which reportedly flattened due to seasonality, competition, and other factors. KSF is investigating whether Geron's leadership breached fiduciary duties or violated state or federal laws.
Law firm investigates Geron Corp officers for possible shareholder duty breaches
Halper Sadeh LLC is investigating whether officers and directors of Geron Corporation (NASDAQ: GERN) breached their fiduciary duties to shareholders. The law firm is seeking to provide long-term Geron stockholders with corporate governance reforms, financial incentives, or other relief, operating on a contingency fee basis. This investigation comes as part of a broader health sector market snapshot provided by Pluang, noting mixed performance among health stocks.
Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?
Halper Sadeh LLP, an investor rights law firm, is investigating whether officers and directors of Geron Corporation (NASDAQ: GERON) breached their fiduciary duties to shareholders. The firm encourages current long-term shareholders to contact them to discuss potential corporate governance reforms, recovery of funds, or other relief. Shareholder involvement is emphasized as a way to improve company policies and enhance shareholder value.
Law firm investigates Geron Corp over alleged misleading revenue claims on cancer drug growth
A law firm, Kahn Swick & Foti, has launched an investigation into Geron Corporation concerning alleged misleading statements by executives about the growth prospects of its cancer drug Rytelo (imetelstat) in 2024. This probe follows a securities class action lawsuit and aims to determine if there were breaches of fiduciary duties or violations of laws. The investigation was initiated after the company reported flattened growth for the drug.
Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN
Kahn Swick & Foti, LLC (KSF) has initiated an investigation into the officers and directors of Geron Corporation (NasdaqGS: GERN). The investigation follows a securities class action lawsuit against Geron and its executives, alleging failure to disclose material information regarding the revenue outlook and growth of its product, imetelstat (Rytelo). KSF is examining whether Geron's leadership breached fiduciary duties or violated state or federal laws, inviting long-term shareholders to provide information.
Analysts Offer Insights on NA Companies: Geron (GERN) and Fair Isaac (FICO)
This article provides analyst insights on two NA sector companies: Geron (GERN) and Fair Isaac (FICO). Geron received a Hold rating from H.C. Wainwright analyst Emily Bodnar, with a strong buy consensus and a target upside of 233.1%. Fair Isaac was reiterated as a Buy by Wells Fargo analyst Jason Haas CFA, with a moderate buy consensus and a target upside of 56.3%.
Geron Eyes High End of 2026 RYTELO Revenue Guidance as Community Adoption Expands
Geron (NASDAQ: GERN) anticipates RYTELO revenue to reach the higher end of its 2026 guidance, targeting approximately $230 million to $240 million, driven by strong community oncology adoption. The company reported record quarterly revenue of $57.5 million and is focusing on expanding RYTELO's use in community settings, where 80% of the lower-risk Myelodysplastic Syndromes (MDS) market resides. Geron also plans to outline its European commercialization strategy by year-end and continues its Phase 3 trial for myelofibrosis, while maintaining over $300 million in cash.
Geron Sees RYTELO Revenue Near High End of 2026 Guidance as Community Use Expands
Geron anticipates RYTELO's 2026 revenue to be at the higher end of its $230 million–$240 million guidance, driven by consistent growth, a 24% increase in first-half revenue, and reduced operating expenses. The company is strategically expanding RYTELO's use in community settings and focusing on earlier-line treatment for lower-risk MDS patients, while also exploring partnership options for European markets. Geron maintains strong financial flexibility with over $320 million in cash and is engaged in regulatory discussions regarding its myelofibrosis study.
Geron to Present at Upcoming Investor Conferences
Geron Corporation announced its participation in two upcoming investor conferences in September 2026. Members of the management team will conduct fireside chats at the 2026 Cantor Global Healthcare Conference and the H.C. Wainwright 28th Annual Global Investment Conference, both held in New York, NY. Live and archived audio webcasts will be available on the company's website.
Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?
Halper Sadeh LLC, an investor rights law firm, is investigating whether officers and directors of Geron Corporation (NASDAQ: GERN) breached their fiduciary duties to shareholders. The firm encourages long-term shareholders to contact them to discuss legal options, which may include seeking corporate governance reforms, the return of funds, or financial incentives. They emphasize that shareholder involvement can enhance transparency and accountability within the company.
Geron Shares Surge 14.7% After Issuing First RYTELO Revenue Guidance of Up to $240 Million
Geron Corporation shares surged 14.7% after the company provided its first full-year RYTELO revenue guidance of $220 million to $240 million and reported a narrowed first-half net loss. The stock closed at $1.48, significantly below analyst consensus targets, reflecting deep disagreement over RYTELO's commercial ramp and the company's path to profitability. The future performance of RYTELO will be crucial in determining if the stock's "undervalued" narrative holds, especially given the company's reliance on a single product and potential future financing needs.
ETFs Investing in Geron Corporation Stocks
This article from TradingView lists various ETFs that include Geron Corporation (GON) stocks in their portfolios. It provides detailed financial data for each ETF, such as market value, weight of GON stock, issuer, management style, expense ratio, assets under management (AUM), price, and 3-year NAV total return. The ETFs cover different investment strategies, including passive and active management, and focus on sectors like healthcare, biotechnology, small-cap, and total market.
Edmond DE Rothschild Holding S.A. Buys New Holdings in Geron Corporation $GERN
Edmond DE Rothschild Holding S.A. has acquired a new position in Geron Corporation, purchasing 2,330,000 shares valued at approximately $2,982,000. This makes Edmond DE Rothschild Holding S.A. an owner of about 0.36% of Geron. Other institutional investors like RA Capital Management L.P., BlackRock Inc., and Vanguard Group Inc. have also significantly modified their holdings in the biopharmaceutical company.
Geron (GERN) After Earnings And New RYTELO Guidance Has The Valuation Story Changed
Geron (GERN) has shown positive stock performance recently following its Q2 and H1 2026 earnings report and new RYTELO guidance, which provides clearer revenue visibility. The company's valuation narrative suggests it is 53.2% undervalued, with a fair value of $3.40 per share, driven by aggressive revenue expansion and pipeline catalysts like myelofibrosis expansion and EU approvals. However, the valuation heavily depends on RYTELO's execution and the telomerase pipeline, making it susceptible to setbacks.
GERN: Future Profit Upside Will Be Driven By Stronger Margin Outlook
Analyst Consensus Target has updated its fair value for Geron (GERN) to $4.25 from $3.40, driven by improved assumptions for revenue growth (44.30% vs 37.82%), profit margin (38.05% vs 22.97%), and a lower future P/E of 14.80. The company also issued earnings guidance for 2026, projecting RYTELO net product revenue between US$220 million and US$240 million. These revised metrics indicate a stronger margin outlook and a more favorable valuation for Geron.
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation announced it granted stock options to six new employees as an inducement to employment, effective August 17, 2026. These options cover 311,250 shares at an exercise price of $1.53, vesting over four years. The grants comply with Nasdaq Listing Rule 5635(c)(4) and are part of Geron's 2018 Inducement Award Plan.
Geron Corporation Reports Inducement Grants U
Geron Corporation announced inducement grants to six new employees, consisting of stock options to purchase 306,000 shares of common stock and restricted stock units for 151,000 shares. These grants, made under Nasdaq Listing Rule 5635(c)(4), were approved by the Compensation Committee and are subject to vesting schedules.
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation announced that it granted stock options to six new employees as an inducement to employment, in accordance with Nasdaq Listing Rule 5635(c)(4). These options cover an aggregate of 311,250 shares of common stock, with an exercise price of $1.53 per share, vesting over four years. Geron is a commercial-stage biopharmaceutical company focused on blood cancer, with its drug RYTELO® approved for certain myelodysplastic syndromes.
RA Capital reports 66.5M-share Geron (GERN) position capped at 9.99% ownership
RA Capital Management, L.P. and associated entities have reported a 9.99% beneficial ownership stake in Geron Corporation (GERN) as of June 30, 2026, totaling 66,502,728 shares. This includes directly held common stock and Pre-Funded Warrants, with a "Beneficial Ownership Blocker" preventing ownership from exceeding 9.99%. The percentage calculation uses 642 million outstanding shares plus 23.7 million shares from warrant exercise, with the official SEC filing rounding down to 9.9%.
GERN|Geron Corp|Price:1.530|Chg%:-0.040
This article provides a detailed overview of Geron Corp (GERN) stock performance, financial data, and analyst ratings. It highlights the company's current stock price, market capitalization, key financial figures, and a "Buy" consensus rating from analysts with a significant upside potential. The profile section describes Geron Corp as a commercial-stage biopharmaceutical company focusing on RYTELO (imetelstat) for treating myelodysplastic syndromes.
Geron Corporation - Common Stock (NQ: GERN)
This page provides recent news headlines and financial updates for Geron Corporation (NASDAQ: GERN). Key topics include Q2 2026 earnings, RYTELO sales performance, and upcoming earnings schedules, along with stock price movements and analyst assessments. The company's RYTELO demand grew, though recent earnings reports have shown mixed results.
GERON CORP 2026: Revenue $57.48M, EPS ($0.02) — 10-Q Summary
Geron Corp (GERN) reported its 2026 quarterly results, with revenue increasing to $57.48 million and a net loss of ($16.68 million), resulting in a diluted loss per share of ($0.02). The revenue growth was primarily driven by a 17% quarter-over-quarter increase in product revenue, attributed to higher patient volume for RYTELO. The company also highlighted its U.S. commercial launch in June 2024 and EU marketing authorization in March 2025 as key developments.
State Street Corporation (GERN) discloses 5.6% beneficial stake in Geron
State Street Corporation has reported a 5.6% beneficial ownership stake in Geron Corp, holding 35,856,671 shares of common stock through its asset management subsidiaries. While State Street holds no sole voting or dispositive power, it maintains shared voting power over 34,097,965 shares and shared dispositive power over all its beneficially owned shares. This disclosure was made via a Schedule 13G SEC filing, indicating a passive investment.
Geron (NASDAQ:GERN) Posts Earnings Results, Misses Expectations By $0.01 EPS
Geron (NASDAQ:GERN) reported its quarterly earnings, missing analyst EPS expectations by $0.01 with a loss of $0.02 per share, although revenue of $57.48 million surpassed estimates. RYTELO revenue increased 17% year-over-year, and the company anticipates 2026 net product revenue to be at the mid-to-high end of its $220 million to $240 million guidance. Shares surged 21.6% despite the EPS miss and ongoing evaluation of its Phase III myelofibrosis trial.
Form 8K Geron Corporation For: 6 August By Investing.com
This article announces the filing of a Form 8K by Geron Corporation on August 6, 2026. The content is brief, primarily serving as a notification of the filing and listing the stock symbol GERN with a daily price change of -5.73%.
Form 8K Geron Corporation For: 6 August By Investing.com
This article from Investing.com announces the filing of a Form 8K by Geron Corporation for August 6. The content provides the title and date of the filing, along with the company's stock symbol and
Geron reports Q2 2026 RYTELO revenue $57.5M; net loss $16.7M; cash $327M
Geron reported Q2 2026 results, announcing RYTELO net product revenue of $57.5 million and a net loss of $16.7 million. The company ended the quarter with $326.9 million in cash and reaffirmed its full-year 2026 guidance for RYTELO revenue and operating expenses. Geron also noted sequential demand growth for RYTELO and expanded its leadership team.
[10-Q] GERON CORP Quarterly Earnings Report
Geron Corporation (GERN) has released its Q2 2026 quarterly earnings report, detailing financial performance for the period ending June 30, 2026. The report indicates that the company had $326.9 million in cash and securities, a decline from $401.1 million at the end of 2025, primarily due to net cash used in operating activities. RYTELO product revenue increased, but the company continues to incur net losses, with an accumulated deficit of approximately $1.9 billion.
GERON CORP 2026: Revenue $57.48M, EPS ($0.02) — 10-Q Summary
GERON CORP (GERN) reported its 2026 quarterly results, with revenue increasing to $57.48 million and a net loss of ($16.68 million), resulting in a diluted EPS of ($0.02). The revenue growth was primarily driven by higher patient volume for RYTELO, while the company also saw a channel shift and made progress with brand and regulatory milestones including a U.S. commercial launch and EU marketing authorization. Operational milestones include the full enrollment of Phase 3 IMpactMF and workforce reductions.
Geron earnings missed by $0.01, revenue topped estimates
Geron (NASDAQ: GERN) reported second-quarter earnings that missed analyst estimates by $0.01, with an EPS of $-0.0200 against an anticipated $-0.0100. However, the company's revenue surpassed expectations, coming in at $57.48 million compared to the consensus estimate of $55.21 million. Despite the revenue beat, Geron's stock price has seen a decline of -3.60% over both the last 3 months and the last 12 months.
Geron Releases Q2 2026 Financial Results
Geron Corporation reported a wider-than-expected loss for Q2 2026, with a net loss per share of -$0.02, exceeding the -$0.01 estimate. Despite the loss, the company's oncology therapeutic RYTELO generated $57.5 million in revenue, surpassing estimates and showing significant year-over-year growth. Geron also provided full-year revenue guidance of $220.0 million to $240.0 million.
Geron stock gains after Q2 revenue beat (GERN:NASDAQ)
Geron (GERN) stock gained 16% after the company reported Q2 2026 revenue that exceeded Street forecasts. This strong performance was driven by sales of its blood cancer therapy, Rytelo. The surge marks Geron's best single-day gain in over two years.
Geron (GERN) Reports Q2 Loss, Beats Revenue Estimates
Geron (GERN) reported a Q2 loss of $0.02 per share, which missed the Zacks Consensus Estimate of a $0.01 loss. However, the company surpassed revenue expectations, posting $57.48 million against an estimate of $55.01 million. Despite the revenue beat, the stock holds a Zacks Rank #4 (Sell) due to unfavorable estimate revisions, suggesting potential underperformance in the near future.
Earnings Flash (GERN) Geron Corporation Reports Q2 Revenue $57.5M, vs. FactSet Est of $55.3M
Geron Corporation announced Q2 revenue of $57.5 million, surpassing the FactSet estimate of $55.3 million. The company also provided earnings guidance for 2026 and reported earnings results for the second quarter and six months ended June 30, 2026. Geron is a commercial-stage biopharmaceutical company focused on developing its telomerase inhibitor, RYTELO, for various myeloid hematologic malignancies.
Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Geron Corporation announced its second quarter 2026 financial results, reporting $57.5 million in RYTELO net product revenue, an 11% increase from Q1 2026. The company reiterated its 2026 guidance for RYTELO net product revenue to be between $220 million and $240 million, and total operating expenses between $230 million and $240 million. Geron ended the quarter with $327 million in cash and marketable securities and highlighted continued demand growth for RYTELO in the U.S. and advancements in its clinical trials.
Earnings Preview: Geron to Report Financial Results Pre-market on August 05
Geron Corporation (GERN) is scheduled to release its financial results on August 5, 2026, before the market opens. Analysts forecast an EPS of -$0.04 and revenue of $4 million for the quarter. Investors will be keenly watching these results to gauge the company's financial health and future prospects.
Geron Corp (GERN) Valuation: PE, PB & Fair Value Analysis
Geron Corp (GERN) currently holds a valuation score of 7.81, placing it 191st out of 384 companies in the Biotechnology & Medical Research industry. The article highlights its P/E ratio of -13.88, which is a significant drop from its recent high, while noting that relevant P/B, P/S, and P/CF data are not yet disclosed by the company. The analysis provides key financial figures and market capitalization for GERN.
Geron Market Sentiment
This article provides an overview of market sentiment for Geron (GERN), highlighting analyst consensus, short interest, options flow, and recent insider activity. Key signals show a "Buy" analyst consensus, 12.5% rising short interest, and a bullish options flow with a 0.01 P/C ratio. The article also lists recent analyst ratings, price target changes, and related news, such as whale activity and insider stock acquisitions.
Geron Corp (GERN) Financial Health: Profitability & Balance Sheet Analysis
Geron Corp (GERN) has a current financial score of 8.58, ranking 41 out of 385 in the Biotechnology & Medical Research industry, indicating a weak financial status but high operating efficiency. The company's latest quarterly revenue saw a 30.89% year-over-year increase, reaching $51.84M, while its net profit increased by 81.64% year-over-year. Key detailed financial data for aspects like cash and cash equivalents, total assets, total liabilities, and free cash flow have not been disclosed yet.
Geron Corp (GERN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey attempts to provide a revenue breakdown for Geron Corp (GERN) by business segments and regional contributions. However, the site states that relevant financial data for these categories have not yet been disclosed by the company. Consequently, no specific revenue figures or breakdowns are presented.
GERN|Geron Corp|Price:1.415|Chg%:-0.035
This article provides a comprehensive stock analysis of Geron Corp (GERN) by TradingKey, highlighting its stable fundamentals, high growth potential, and fair valuation within the Biotechnology & Medical Research industry. Despite positive analyst ratings and recent market outperformance, technical indicators suggest the stock is trading sideways. The analysis details key insights such as high institutional ownership, accelerated revenue growth, and specific strengths and risks related to its biopharmaceutical pipeline.
Geron Corp (GERN) Cash Flow
This article provides a detailed historical cash flow statement for Geron Corp (GERN), covering quarterly and annual data for operating, investing, and financing activities. It breaks down various components of cash flow and offers definitions for key financial metrics like operating cash flow, investing cash flow, financing cash flow, and free cash flow. The data highlights Geron Corp's past cash flow performance and changes year-over-year.
Geron Corp (GERN) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Geron Corp (GERN), listing major shareholders and their proportional holdings, along with a breakdown by shareholder type. It also provides a historical overview of institutional shareholding data and recent shareholder activity, including changes in holdings by key investors, and lists related ETFs that include GERN.
TradingKey
This page provides a detailed quarterly and annual income statement for Geron Corp (GERN), allowing users to analyze the company's financial performance and operational efficiency. It presents various financial metrics including revenue, operating expenses, net income, and earnings per share, along with year-over-year comparisons. The page also includes an FAQ section explaining how to read the income statement and defining key financial terms.
Geron Corp (GERN) Institutional Confidence
Geron Corp (GERN) has an institutional shareholding score of 7.00, placing it 80th in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 76.90%, showing a quarter-over-quarter decrease of 5.14%. Steven Cohen is the largest institutional shareholder, holding 3.19% of the outstanding shares.
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation announced inducement grants of stock options to five new employees. These grants, totaling 202,500 shares of common stock, were made effective July 17, 2026, with an exercise price of $1.44 per share and a ten-year term, vesting over four years. The grants comply with Nasdaq Listing Rule 5635(c)(4) and aim to incentivize the employees' acceptance of employment.
Five New Geron Hires Receive Options at $1.44 Per Share
Geron (Nasdaq: GERN) has granted stock options for a total of 202,500 common shares to five new employees, effective July 17, 2026, as an inducement for their employment. The options have an exercise price of $1.44 per share, matching the closing price on the grant date, and come with a ten-year term and a four-year vesting schedule. This action aligns with Nasdaq Listing Rule 5635(c)(4) and Geron's 2018 Inducement Award Plan.
